Breast cancer in the elderly

Diana Crivellari, Matti Aapro, Robert Leonard, Gunter Von Minckwitz, Etienne Brain, Aron Goldhirsch, Andrea Veronesi, Hyman Muss

Research output: Contribution to journalArticle

Abstract

Screening and adjuvant postoperative therapies have increased survival among women with breast cancer. These tools are seldom applied in elderly patients, although the usually reported incidence of breast cancer is close to 50% in women 65 years or older, reaching 47% after 70 years in the updated Surveillance, Epidemiology, and End Results (SEER) database. Elderly breast cancer patients, even if in good medical health, were frequently excluded from adjuvant clinical trials. Women age 70 years who are fit actually have a median life expectancy of 15.5 years, ie, half of them will live much longer and will remain exposed for enough time to the potentially preventable risks of a relapse and specific death. In the last few years, a new concern about this issue has developed. Treatment now faces two major end points, as in younger women: to improve disease-free survival in the early stages, and to palliate symptoms in advanced disease. However, in both settings, the absolute benefit of treatment is critical because protecting quality of life and all its related aspects (especially functional status and independence), is crucial in older persons who have more limited life expectancy. Furthermore, the new hormonal compounds (aromatase inhibitors) and chemotherapeutic drugs (capecitabine, liposomal doxorubicin), are potentially less toxic than and equally as effective as older more established therapies. These new treatments bring new challenges including higher cost, and defining their benefit in elderly breast cancer must include an analysis of the cost/benefit ratio. These issues emphasize the urgent need to develop and support clinical trials for this older population of breast cancer patients both in the adjuvant and metastatic settings, a move that will take us from a prejudiced, age-based medicine to an evidence-based medicine.

Original languageEnglish
Pages (from-to)1882-1890
Number of pages9
JournalJournal of Clinical Oncology
Volume25
Issue number14
DOIs
Publication statusPublished - May 10 2007

Fingerprint

Breast Neoplasms
Life Expectancy
Clinical Trials
Therapeutics
Aromatase Inhibitors
Poisons
Evidence-Based Medicine
Disease-Free Survival
Cost-Benefit Analysis
Epidemiology
Quality of Life
Databases
Costs and Cost Analysis
Recurrence
Survival
Incidence
Health
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Crivellari, D., Aapro, M., Leonard, R., Von Minckwitz, G., Brain, E., Goldhirsch, A., ... Muss, H. (2007). Breast cancer in the elderly. Journal of Clinical Oncology, 25(14), 1882-1890. https://doi.org/10.1200/JCO.2006.10.2079

Breast cancer in the elderly. / Crivellari, Diana; Aapro, Matti; Leonard, Robert; Von Minckwitz, Gunter; Brain, Etienne; Goldhirsch, Aron; Veronesi, Andrea; Muss, Hyman.

In: Journal of Clinical Oncology, Vol. 25, No. 14, 10.05.2007, p. 1882-1890.

Research output: Contribution to journalArticle

Crivellari, D, Aapro, M, Leonard, R, Von Minckwitz, G, Brain, E, Goldhirsch, A, Veronesi, A & Muss, H 2007, 'Breast cancer in the elderly', Journal of Clinical Oncology, vol. 25, no. 14, pp. 1882-1890. https://doi.org/10.1200/JCO.2006.10.2079
Crivellari D, Aapro M, Leonard R, Von Minckwitz G, Brain E, Goldhirsch A et al. Breast cancer in the elderly. Journal of Clinical Oncology. 2007 May 10;25(14):1882-1890. https://doi.org/10.1200/JCO.2006.10.2079
Crivellari, Diana ; Aapro, Matti ; Leonard, Robert ; Von Minckwitz, Gunter ; Brain, Etienne ; Goldhirsch, Aron ; Veronesi, Andrea ; Muss, Hyman. / Breast cancer in the elderly. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 14. pp. 1882-1890.
@article{64b4127387354a21b09d6610d65a41fb,
title = "Breast cancer in the elderly",
abstract = "Screening and adjuvant postoperative therapies have increased survival among women with breast cancer. These tools are seldom applied in elderly patients, although the usually reported incidence of breast cancer is close to 50{\%} in women 65 years or older, reaching 47{\%} after 70 years in the updated Surveillance, Epidemiology, and End Results (SEER) database. Elderly breast cancer patients, even if in good medical health, were frequently excluded from adjuvant clinical trials. Women age 70 years who are fit actually have a median life expectancy of 15.5 years, ie, half of them will live much longer and will remain exposed for enough time to the potentially preventable risks of a relapse and specific death. In the last few years, a new concern about this issue has developed. Treatment now faces two major end points, as in younger women: to improve disease-free survival in the early stages, and to palliate symptoms in advanced disease. However, in both settings, the absolute benefit of treatment is critical because protecting quality of life and all its related aspects (especially functional status and independence), is crucial in older persons who have more limited life expectancy. Furthermore, the new hormonal compounds (aromatase inhibitors) and chemotherapeutic drugs (capecitabine, liposomal doxorubicin), are potentially less toxic than and equally as effective as older more established therapies. These new treatments bring new challenges including higher cost, and defining their benefit in elderly breast cancer must include an analysis of the cost/benefit ratio. These issues emphasize the urgent need to develop and support clinical trials for this older population of breast cancer patients both in the adjuvant and metastatic settings, a move that will take us from a prejudiced, age-based medicine to an evidence-based medicine.",
author = "Diana Crivellari and Matti Aapro and Robert Leonard and {Von Minckwitz}, Gunter and Etienne Brain and Aron Goldhirsch and Andrea Veronesi and Hyman Muss",
year = "2007",
month = "5",
day = "10",
doi = "10.1200/JCO.2006.10.2079",
language = "English",
volume = "25",
pages = "1882--1890",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - Breast cancer in the elderly

AU - Crivellari, Diana

AU - Aapro, Matti

AU - Leonard, Robert

AU - Von Minckwitz, Gunter

AU - Brain, Etienne

AU - Goldhirsch, Aron

AU - Veronesi, Andrea

AU - Muss, Hyman

PY - 2007/5/10

Y1 - 2007/5/10

N2 - Screening and adjuvant postoperative therapies have increased survival among women with breast cancer. These tools are seldom applied in elderly patients, although the usually reported incidence of breast cancer is close to 50% in women 65 years or older, reaching 47% after 70 years in the updated Surveillance, Epidemiology, and End Results (SEER) database. Elderly breast cancer patients, even if in good medical health, were frequently excluded from adjuvant clinical trials. Women age 70 years who are fit actually have a median life expectancy of 15.5 years, ie, half of them will live much longer and will remain exposed for enough time to the potentially preventable risks of a relapse and specific death. In the last few years, a new concern about this issue has developed. Treatment now faces two major end points, as in younger women: to improve disease-free survival in the early stages, and to palliate symptoms in advanced disease. However, in both settings, the absolute benefit of treatment is critical because protecting quality of life and all its related aspects (especially functional status and independence), is crucial in older persons who have more limited life expectancy. Furthermore, the new hormonal compounds (aromatase inhibitors) and chemotherapeutic drugs (capecitabine, liposomal doxorubicin), are potentially less toxic than and equally as effective as older more established therapies. These new treatments bring new challenges including higher cost, and defining their benefit in elderly breast cancer must include an analysis of the cost/benefit ratio. These issues emphasize the urgent need to develop and support clinical trials for this older population of breast cancer patients both in the adjuvant and metastatic settings, a move that will take us from a prejudiced, age-based medicine to an evidence-based medicine.

AB - Screening and adjuvant postoperative therapies have increased survival among women with breast cancer. These tools are seldom applied in elderly patients, although the usually reported incidence of breast cancer is close to 50% in women 65 years or older, reaching 47% after 70 years in the updated Surveillance, Epidemiology, and End Results (SEER) database. Elderly breast cancer patients, even if in good medical health, were frequently excluded from adjuvant clinical trials. Women age 70 years who are fit actually have a median life expectancy of 15.5 years, ie, half of them will live much longer and will remain exposed for enough time to the potentially preventable risks of a relapse and specific death. In the last few years, a new concern about this issue has developed. Treatment now faces two major end points, as in younger women: to improve disease-free survival in the early stages, and to palliate symptoms in advanced disease. However, in both settings, the absolute benefit of treatment is critical because protecting quality of life and all its related aspects (especially functional status and independence), is crucial in older persons who have more limited life expectancy. Furthermore, the new hormonal compounds (aromatase inhibitors) and chemotherapeutic drugs (capecitabine, liposomal doxorubicin), are potentially less toxic than and equally as effective as older more established therapies. These new treatments bring new challenges including higher cost, and defining their benefit in elderly breast cancer must include an analysis of the cost/benefit ratio. These issues emphasize the urgent need to develop and support clinical trials for this older population of breast cancer patients both in the adjuvant and metastatic settings, a move that will take us from a prejudiced, age-based medicine to an evidence-based medicine.

UR - http://www.scopus.com/inward/record.url?scp=34249829868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249829868&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.10.2079

DO - 10.1200/JCO.2006.10.2079

M3 - Article

C2 - 17488987

AN - SCOPUS:34249829868

VL - 25

SP - 1882

EP - 1890

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -